CA2401014A1 - Procede de conception de medicaments fondes sur la structure utilisant la spectrometrie de masse et la resonance magnetique nucleaire - Google Patents

Procede de conception de medicaments fondes sur la structure utilisant la spectrometrie de masse et la resonance magnetique nucleaire Download PDF

Info

Publication number
CA2401014A1
CA2401014A1 CA002401014A CA2401014A CA2401014A1 CA 2401014 A1 CA2401014 A1 CA 2401014A1 CA 002401014 A CA002401014 A CA 002401014A CA 2401014 A CA2401014 A CA 2401014A CA 2401014 A1 CA2401014 A1 CA 2401014A1
Authority
CA
Canada
Prior art keywords
compound
target molecule
complex
target
bound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002401014A
Other languages
English (en)
Inventor
Franklin Joseph Moy
Marshall Mayer Siegel
Dominick Mobilio
Robert Powers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2401014A1 publication Critical patent/CA2401014A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Procédé de conception de médicaments fondés sur la structure utilisant la spectrométrie de masse et la résonance magnétique nucléaire.
CA002401014A 2000-02-25 2001-02-21 Procede de conception de medicaments fondes sur la structure utilisant la spectrometrie de masse et la resonance magnetique nucleaire Abandoned CA2401014A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51380600A 2000-02-25 2000-02-25
US09/513,806 2000-02-25
PCT/US2001/005495 WO2001062688A2 (fr) 2000-02-25 2001-02-21 Procede de conception de medicaments fondes sur la structure utilisant la spectrometrie de masse et la resonance magnetique nucleaire

Publications (1)

Publication Number Publication Date
CA2401014A1 true CA2401014A1 (fr) 2001-08-30

Family

ID=24044740

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002401014A Abandoned CA2401014A1 (fr) 2000-02-25 2001-02-21 Procede de conception de medicaments fondes sur la structure utilisant la spectrometrie de masse et la resonance magnetique nucleaire

Country Status (9)

Country Link
EP (1) EP1259469A2 (fr)
JP (1) JP2003524167A (fr)
CN (1) CN1411554A (fr)
AR (1) AR027955A1 (fr)
AU (1) AU2001238584A1 (fr)
BR (1) BR0108606A (fr)
CA (1) CA2401014A1 (fr)
MX (1) MXPA02008253A (fr)
WO (1) WO2001062688A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002364783A1 (en) * 2001-11-21 2003-06-10 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in general metabolism

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891742A (en) * 1995-01-19 1999-04-06 Chiron Corporation Affinity selection of ligands by mass spectroscopy
US5698401A (en) * 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
ES2159056T5 (es) * 1995-11-14 2007-07-16 Abbott Laboratories Utilizacion de la resonancia magnetica nuclear para diseñar ligandos que se unen a biomoleculas blanco.
CA2242171A1 (fr) * 1996-04-08 1997-10-16 Glaxo Group Limited Codage et analyse quantitative de banques combinatoires fondes sur la masse
JP3788909B2 (ja) * 1999-02-12 2006-06-21 セテク コーポレイション 親和力配位子について複合生理学的材料をスクリーニングする高処理量のサイズ排除法

Also Published As

Publication number Publication date
BR0108606A (pt) 2003-01-07
WO2001062688A2 (fr) 2001-08-30
AU2001238584A1 (en) 2001-09-03
CN1411554A (zh) 2003-04-16
WO2001062688A3 (fr) 2002-03-14
EP1259469A2 (fr) 2002-11-27
MXPA02008253A (es) 2002-11-29
AR027955A1 (es) 2003-04-16
JP2003524167A (ja) 2003-08-12

Similar Documents

Publication Publication Date Title
Wales et al. Hydrogen exchange mass spectrometry for the analysis of protein dynamics
Hüttenhain et al. Perspectives of targeted mass spectrometry for protein biomarker verification
Graziadei et al. Leveraging crosslinking mass spectrometry in structural and cell biology
Arul et al. Sample multiplexing strategies in quantitative proteomics
Rodríguez‐Suárez et al. The application of quantification techniques in proteomics for biomedical research
JP4672615B2 (ja) 迅速かつ定量的なプロテオーム解析および関連した方法
Leurs et al. Getting to the core of protein pharmaceuticals–comprehensive structure analysis by mass spectrometry
US9470692B2 (en) Mass spectrometric analysis
US9222943B2 (en) Mass spectrometry-cleavable cross-linking agents to facilitate structural analysis of proteins and protein complexes, and method of using same
US20030068825A1 (en) System and method of determining proteomic differences
Schmidt et al. High-accuracy proteome maps of human body fluids
Fu et al. Automated proteomic sample preparation: The key component for high throughput and quantitative mass spectrometry analysis
Poetz et al. Proteome wide screening using peptide affinity capture
Schiel Glycoprotein analysis using mass spectrometry: unraveling the layers of complexity
Froehlich et al. Systematic optimization of the iMALDI workflow for the robust and straightforward quantification of signaling proteins in cancer cells
Pisitkun et al. Tandem mass spectrometry in physiology
Sap et al. Labeling methods in mass spectrometry based quantitative proteomics
US20010046684A1 (en) Methods of structure-based drug design using MS/MNR
CA2401014A1 (fr) Procede de conception de medicaments fondes sur la structure utilisant la spectrometrie de masse et la resonance magnetique nucleaire
Opiteck et al. Target class strategies in mass spectrometry-based proteomics
Lehmann et al. From “Clinical Proteomics” to “Clinical Chemistry Proteomics”: considerations using quantitative mass-spectrometry as a model approach
Wang et al. Quantitative proteomics in development of disease protein biomarkers
EP1404707A1 (fr) Systemes et procedes d'analyse de proteines
Courouble et al. Advances in Mass Spectrometry‐Based Structural Proteomics: Development of HDX‐MS and XL‐MS Techniques from Recombinant Protein to Cellular Systems
Mandell et al. Application of amide proton exchange mass spectrometry for the study of protein‐protein interactions

Legal Events

Date Code Title Description
FZDE Discontinued